Search results
Results from the WOW.Com Content Network
Heart Benefits: Medications in the SGLT-2 inhibitor or GLP-1 receptor agonist class may ofer heart benefits for people with cardiovascular disease. Talk to your doctor about your options and whether switching to one of these drugs may help you.
Compare SGLT-2 inhibitors (sodium-glucose cotransporter-2 inhibitors). View important safety information, ratings, user reviews, popularity and more.
There are currently four SGLT2 inhibitors licensed in the UK for the management of type 2 diabetes (T2DM). There are a number of differences between the SGLT2 inhibitors; these include: Indications and dose. Interactions. Use in hepatic impairment. Use in renal impairment.
SGLT2 Inhibitors. Reduces glucose (sugar) levels in your body by increasing the amount of sugar you pass in your urine. Canagliflozin (Invokana®), Dapagliflozin (ForxigaTM), Empagliflozin (JardianceTM) • Canagliflozin 100 mg may be increased to 300 mg (Your dose may depend on your kidney function) • Dapagliflozin 5 mg may be increased to ...
SGLT2 inhibitors decrease renal glucose reabsorption and increase urinary glucose excretion, reducing fasting and postprandial blood glucose levels . Reduce A1C 0.5-1% . Weight loss (0.1-4 kg)of the day. Reduce systolic blood pressure . No hypoglycemia when used as monotherapy .
SGLT2 inhibitors have demonstrated efficacy in lowering glycosylated hemoglobin (HbA1c) levels by ~0.5% to 1% (Inzucchi et al 2015). They have been studied as monotherapy and in combination with other antidiabetic agents. Most trials evaluated the addition of an SGLT2 inhibitor to one or more classes of antidiabetic agents.
SGLT2 inhibitor (continued) • Caution when combined with very low carbohydrate eating patterns and/or with suspected insulin deciency • Risk of Diabetic Ketoacidosis (DKA), which may occur without hyperglycemia, rare in type 2 diabetes: treat promptly if suspected – Signs of DKA may include nausea, vomiting, lack of appetite, abdominal
Indications, doses and licences of SGLT2 inhibitors, by indication. Indication. Drug and dose Initiate Stop/reduce. Notes. Insufficiently controlled type 2 diabetes (as an adjunct to diet and exercise) Stop if eGFR persistently <30 and ACR ≤30 mg/mmol.*.
Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. JACC: Heart Failure . 2019;7(2):169-172. doi:10.1016/j. jchf.2018.11.013; 7. Petrie MC, Verma S, Docherty KF, et al.
Need to kNow: SGLt2 iNhibitorS. Indications, doses and starting/stopping recommendations of SGLT2 inhibitors, by drug name. eGFR presented in mL/min/1.73 m2; ACR presented in mg/mmol.